Speaking with TCTMD, lead author Jeffrey I. Presented in a late-breaking science session at the virtual American Heart Association 2021 Scientific Sessions and published simultaneously in the New England Journal of Medicine, AXIOMATIC-TKR was a phase II trial of patients undergoing elective knee arthroplasty who were randomized to oral milvexian or injectable enoxaparin. The oral factor XIa inhibitor milvexian is a promising option for preventing venous thromboembolism (VTE) while keeping bleeding risk low, according to the randomized AXIOMATIC-TKR trial.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |